Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0.37% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 2.11% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 0.4% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 2.8% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0.37% of any dividend from IPCALAB should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
Gradual 3–6 month gains, 50-day above 200-day, and price relatively close to its 52-week high point to a moderate uptrend with controlled volatility. Pharma is not in the listed sentiment groups, so external alignment is described as neutral.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.